Prevention strategies for cytomegalovirus disease and long-term outcomes in the high-risk transplant patient (D+/R-): Experience from the RESITRA-REIPI cohort

Y. Meije, J. Fortún, O. Len, J. M. Aguado, A. Moreno, J. M. Cisneros, M. Gurguí, J. Carratalà, P. Muñoz, M. Montejo, M. Blanes, G. Bou, J. L. Pérez, J. Torre-Cisneros, A. Ramos, A. Pahissa, J. Gavaldà

Research output: Contribution to journalArticleResearchpeer-review

20 Citations (Scopus)

Abstract

Background: Cytomegalovirus (CMV)-negative recipients of a graft from a CMV-positive donor (D+/R-) are at high risk of CMV disease. Current preventive strategies include universal prophylaxis (UP) and preemptive therapy (PT). However, the best strategy to prevent CMV disease and achieve better long-term outcomes remains a matter of debate. Methods: We analyzed the incidence of CMV disease and long-term outcomes including graft dysfunction and patient mortality at 5 years after transplantation with both preventive strategies. High-risk (D+/R-) kidney and liver transplant recipients from the RESITRA cohort were included. Results: Of 2410 kidney or liver transplant patients, 195 (8.3%) were D+/R- The final cohort included 58 liver and 102 kidney recipients. UP was given in 92 patients and 68 received PT; 10.9% and 36.8% developed CMV disease, respectively (P < 0.01). The independent risk factors for CMV disease were PT strategy (hazard ratio [HR], 3.30; 95% confidence interval [CI], 1.6-6.9), kidney transplantation (HR, 3.8; 95% CI, 1.4-9.9), and cyclosporine immunosuppression (HR, 2.4; 95% CI, 1.2-4.7). PT strategy was also a risk factor for CMV disease in both liver transplantation (HR, 11.0; 95% CI, 1.2-98.7) and kidney transplantation (HR, 2.7; 95% CI, 1.3-6.0), independently. The development of CMV replication during the first 2 years after transplantation was a risk factor for graft dysfunction at 5 years after transplantation (odds ratio, 3.4; 95% CI, 1.3-9.0). Nevertheless, no significant differences were seen in either graft dysfunction or mortality between the 2 strategies. Conclusions: The study supports the benefit of the UP strategy to prevent CMV disease in D+/R- liver or kidney transplant patients. The development of CMV replication during the first 2 years after transplantation was associated with graft dysfunction at 5 years after transplantation. © 2014 Wiley Periodicals, Inc.163 June 2014 10.1111/tid.12226 Original Article Original articles © 2014 John Wiley & Sons A/S.
Original languageEnglish
Pages (from-to)387-396
JournalTransplant Infectious Disease
Volume16
Issue number3
DOIs
Publication statusPublished - 1 Jan 2014

Keywords

  • Cytomegalovirus
  • Graft dysfunction
  • Preemptive therapy
  • Transplantation
  • Universal prophylaxis

Fingerprint Dive into the research topics of 'Prevention strategies for cytomegalovirus disease and long-term outcomes in the high-risk transplant patient (D+/R-): Experience from the RESITRA-REIPI cohort'. Together they form a unique fingerprint.

Cite this